These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19884645)

  • 1. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
    Birnkrant D; Cox E
    N Engl J Med; 2009 Dec; 361(23):2204-7. PubMed ID: 19884645
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.
    Arya V; Carter WW; Robertson SM
    Clin Pharmacol Ther; 2010 Nov; 88(5):587-9. PubMed ID: 20959843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emergency use authorization of peramivir IV: a view from the manufacturer.
    Hollister AS; Sheridan WP
    Clin Pharmacol Ther; 2011 Feb; 89(2):172-4. PubMed ID: 21252934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Emergency admission of peramivir in the U.S.A].
    Bennack E; Holzgrabe U
    Pharm Unserer Zeit; 2010; 39(1):9-10. PubMed ID: 20033965
    [No Abstract]   [Full Text] [Related]  

  • 5. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
    Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
    Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous peramivir emergency use authorization 2009: update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2010; 24(2):51-3. PubMed ID: 20168138
    [No Abstract]   [Full Text] [Related]  

  • 7. Peramivir and its use in H1N1 influenza.
    Castillo R; Holland LE; Boltz DA
    Drugs Today (Barc); 2010 Jun; 46(6):399-408. PubMed ID: 20571608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency-use authorization of peramivir.
    Gonzalez R; Massoomi F; Neff W
    Am J Health Syst Pharm; 2009 Dec; 66(24):2162-3. PubMed ID: 19966083
    [No Abstract]   [Full Text] [Related]  

  • 9. Peramivir for the treatment of influenza.
    Shetty AK; Peek LA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losing the opportunity to study influenza drugs.
    Meyerhoff A; Lietman P
    JAMA; 2010 Mar; 303(9):878-9. PubMed ID: 20197536
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergency authorization of medical products: regulatory challenges from the 2009 H1N1 influenza pandemic in Japan.
    Urushihara H; Matsui S; Kawakami K
    Biosecur Bioterror; 2012 Dec; 10(4):372-82. PubMed ID: 23210832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.
    Yu Y; Garg S; Yu PA; Kim HJ; Patel A; Merlin T; Redd S; Uyeki TM
    Clin Infect Dis; 2012 Jul; 55(1):8-15. PubMed ID: 22491506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to several recent publications related to safety and efficacy of peramivir from the emergency use authorization experience.
    Ison MG; Hollister AS; Sheridan WP
    Clin Infect Dis; 2013 Jan; 56(1):164. PubMed ID: 22972863
    [No Abstract]   [Full Text] [Related]  

  • 14. Balancing societal needs and regulatory certainty: the case study of peramivir in Japan.
    Tominaga T; Ando Y; Nagai N; Sato J; Kondo T
    Clin Pharmacol Ther; 2013 Apr; 93(4):342-4. PubMed ID: 23422872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation.
    Komeda T; Ishii S; Itoh Y; Ariyasu Y; Sanekata M; Yoshikawa T; Shimada J
    J Infect Chemother; 2015 Mar; 21(3):194-201. PubMed ID: 25523716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial commentary: What did we learn from the emergency use authorization of peramivir in 2009?
    Pavia AT
    Clin Infect Dis; 2012 Jul; 55(1):16-8. PubMed ID: 22491500
    [No Abstract]   [Full Text] [Related]  

  • 17. RWJ-270201 BioCryst Pharmaceuticals/Johnson & Johnson.
    Barnard DL
    Curr Opin Investig Drugs; 2000 Dec; 1(4):421-4. PubMed ID: 11249693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
    Bantia S; Upshaw R; Babu YS
    Antiviral Res; 2011 Sep; 91(3):288-91. PubMed ID: 21722670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs: Lines of defence.
    Palmer R
    Nature; 2011 Dec; 480(7376):S9-10. PubMed ID: 22158299
    [No Abstract]   [Full Text] [Related]  

  • 20. Peramivir: an intravenous neuraminidase inhibitor.
    McLaughlin MM; Skoglund EW; Ison MG
    Expert Opin Pharmacother; 2015; 16(12):1889-900. PubMed ID: 26153242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.